Quince Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Quince Therapeutics, Inc. (QNCX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$15.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-14
- Quince Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$7.93M, a 3989.22% decline year-over-year.
- Quince Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$7.16M, a 896.77% decline year-over-year.
- Quince Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $5.30M, a 891.40% increase year-over-year.
- Quince Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$631.00K, a 177.05% decline year-over-year.
- Quince Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $5.78M, a 441.33% increase from fiscal 2024.
- Quince Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.07M.
- Quince Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$1.97M.
- Quince Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$6.66M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$7.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$15.10M 10-Q · filed 2026-08-14 | -$9.79M derived: sum of 3 quarters · filed 2026-08-14 | -$10.42M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$7.16M 10-Q · filed 2026-05-11 | -$1.86M derived: sum of 2 quarters · filed 2026-05-11 | -$2.49M derived: sum of 3 quarters · filed 2026-05-11 | -$2.29M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $4.67M derived: sum of 2 quarters · filed 2026-04-10 | $4.88M derived: sum of 3 quarters · filed 2026-08-14 | $5.78M 10-K · filed 2026-04-10 | |||
| 2025-09-30 | -$631.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$427.00K derived: sum of 2 quarters · filed 2026-08-14 | $472.00K 10-Q · filed 2025-11-12 | $1.01M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.10M 10-Q · filed 2026-08-14 | $1.08M 10-Q · filed 2025-08-11 | $1.64M derived: sum of 3 quarters · filed 2026-08-14 | $2.46M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $899.00K 10-Q · filed 2026-05-11 | $898.00K 10-Q · filed 2025-05-13 | $1.43M derived: sum of 2 quarters · filed 2026-05-11 | $2.25M derived: sum of 3 quarters · filed 2026-05-11 | $2.35M derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $535.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $1.35M derived: sum of 2 quarters · filed 2026-04-10 | $1.45M derived: sum of 3 quarters · filed 2026-04-10 | $1.07M 10-K · filed 2026-04-10 | $1.18M 10-K · filed 2025-03-24 | ||
| 2024-09-30 | $819.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $913.00K derived: sum of 2 quarters · filed 2025-11-12 | $532.00K 10-Q · filed 2025-11-12 | -$864.00K derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$287.00K 10-Q · filed 2025-08-11 | -$1.68M derived: sum of 3 quarters · filed 2025-08-11 | -$1.44M derived: sum of 4 quarters · filed 2025-08-11 | |||
| 2024-03-31 | -$381.00K 10-Q · filed 2025-05-13 | -$1.78M derived: sum of 2 quarters · filed 2025-05-13 | -$1.53M derived: sum of 3 quarters · filed 2025-05-13 | -$1.51M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$1.15M derived: sum of 2 quarters · filed 2025-03-24 | -$1.13M derived: sum of 3 quarters · filed 2025-03-24 | -$1.97M 10-K · filed 2025-03-24 | |||
| 2023-09-30 | $243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $268.00K derived: sum of 2 quarters · filed 2024-11-13 | -$576.00K 10-Q · filed 2024-11-13 | -$1.93M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$819.00K 10-Q · filed 2024-08-13 | -$2.17M derived: sum of 3 quarters · filed 2024-08-13 | -$2.46M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | -$844.00K 10-Q · filed 2024-05-13 | -$2.20M derived: sum of 2 quarters · filed 2024-05-13 | -$2.49M derived: sum of 3 quarters · filed 2024-05-13 | -$4.61M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | -$1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$1.65M derived: sum of 2 quarters · filed 2024-04-01 | -$3.77M derived: sum of 3 quarters · filed 2024-04-01 | -$6.66M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$2.41M derived: sum of 2 quarters · filed 2023-11-14 | -$5.30M 10-Q · filed 2023-11-14 | -$7.27M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | -$2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$5.01M 10-Q · filed 2023-08-03 | -$6.98M derived: sum of 3 quarters · filed 2023-08-03 | -$7.09M derived: sum of 4 quarters · filed 2023-08-03 | |||
| 2022-03-31 | -$2.89M 10-Q · filed 2023-05-15 | -$4.86M derived: sum of 2 quarters · filed 2023-05-15 | -$4.97M derived: sum of 3 quarters · filed 2023-05-15 | -$9.15M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$2.08M derived: sum of 2 quarters · filed 2023-03-15 | -$6.26M derived: sum of 3 quarters · filed 2023-03-15 | -$4.63M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | -$107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$4.29M derived: sum of 2 quarters · filed 2022-11-09 | -$2.66M 10-Q · filed 2022-11-09 | -$1.28M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | -$4.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$2.56M 10-Q · filed 2022-08-09 | -$1.18M derived: sum of 3 quarters · filed 2022-08-09 | $2.25M derived: sum of 4 quarters · filed 2022-08-09 | |||
| 2021-03-31 | $1.62M 10-Q · filed 2022-05-10 | $3.00M derived: sum of 2 quarters · filed 2022-05-10 | $6.43M derived: sum of 3 quarters · filed 2022-05-10 | $6.72M derived: sum of 4 quarters · filed 2022-05-10 | |||
| 2020-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.80M derived: sum of 2 quarters · filed 2022-03-01 | $5.10M derived: sum of 3 quarters · filed 2022-03-01 | $7.38M 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $3.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $3.72M derived: sum of 2 quarters · filed 2021-10-29 | $6.00M 10-Q · filed 2021-10-29 | $7.99M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $297.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $2.58M 10-Q · filed 2021-08-06 | $4.57M derived: sum of 3 quarters · filed 2022-03-01 | $6.49M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $2.28M 10-Q · filed 2021-05-06 | $4.27M derived: sum of 2 quarters · filed 2022-03-01 | $6.19M derived: sum of 3 quarters · filed 2022-03-01 | $6.38M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.91M derived: sum of 2 quarters · filed 2022-03-01 | $4.09M derived: sum of 3 quarters · filed 2022-03-01 | $4.86M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $2.11M derived: sum of 2 quarters · filed 2020-11-12 | $2.87M 10-Q · filed 2020-11-12 | $3.10M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-06-30 | $185.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $947.00K 10-Q · filed 2020-08-14 | $1.18M derived: sum of 3 quarters · filed 2021-03-01 | $1.33M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-03-31 | $762.00K 10-Q · filed 2020-05-12 | $996.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.14M derived: sum of 3 quarters · filed 2021-03-01 | $1.31M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2018-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $379.00K derived: sum of 2 quarters · filed 2021-03-01 | $549.00K derived: sum of 3 quarters · filed 2021-03-01 | $273.00K 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $145.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $315.00K derived: sum of 2 quarters · filed 2019-11-12 | $39.00K 10-Q · filed 2019-11-12 | ||||
| 2018-06-30 | $170.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$106.00K 10-Q · filed 2019-08-09 | |||||
| 2018-03-31 | -$276.00K 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |